1. Introduction {#sec1}
===============

The gut microbiota consists predominantly of phyla members *Bacteroidetes* and *Firmicutes*, and to a lesser extent of *Actinobacteria* and *Proteobacteria*\[[@B1], [@B2]\]. There is an estimated 500 to 1,000 different bacterial species represented throughout the human intestine \[[@B3]\]. The number of colony forming units has been calculated at a range from 10^13^ to 10^14^, exceeding the number of human cells by factor of 10 \[[@B4]\]. The enteric bacterial flora as a whole is essential to the normal development and function of the intestine. Salvage of unabsorbed carbohydrates, converted into short-chain fatty acids by bacterial enzymes, is an essential energy source for intestinal epithelial cell and barrier function. The colonic microflora is also central to the synthesis of vitamins B and K \[[@B5]\], and maintenance of intestinal innate and adaptive immune response \[[@B3]\]. On the other side, there is mounting evidence that the intestinal microflora can induce, transfer, and prevent conditions like obesity, type I diabetes, and inflammatory bowel disease (IBD) with a detrimental effect on human health \[[@B6]\]. The focus of this paper is to summarize the evidence for a role of enteric bacteria in the pathogenesis of ulcerative colitis (UC).

Computational data mining by canonical correlation analysis confirmed the critical and disease-relevant interaction of mucosa-associated bacteria and host in IBD \[[@B7]\]. Bacterial interactions with the host were found to be of cyclic nature with an increase in disease inducing bacterial strains and host immune response during active intestinal inflammation. But dysbiosis, defined as quantitative and qualitative microbial imbalance in the gut, is only one factor contributing to intestinal inflammation as seen in UC. Investigating the mucosal immune response, it has been shown that patients with UC mount an immunoglobulin response against endogenous bacterial components. In UC, the DNase-sensitive neutrophil autoantibody with atypical perinuclear distribution (pANCA) was found to be directed against two bacterial antigens: an unidentified 100 kDa protein from *Bacteroides caccae* and outer membrane porin C (OmpC) from *E. coli* strains \[[@B8]\]. Given pANCA\'s low sensitivity, it should not be used as a screening tool for IBD in the general population, but might aid in distinguishing UC from Crohn\'s disease (CD) when used in combination with anti-*Saccharomyces cerevisiae* antibody (ASCA), in particular when surgery is entertained. A combination of positive pANCA and negative ASCA predicted UC correctly in 64% of cases \[[@B9]\]. Other more controversial findings regarding the role of pANCA in UC include its association with severe, relapsing and therapy-refractory left-sided disease, early colectomy for an aggressive course, and higher requirements for immunomodulatory therapy \[[@B9]\]. Additional immunological findings revealed that the intestinal mucosa of patients suffering from UC is infiltrated with Th17 cells \[[@B10]\], stimulated by IL-23, a cytokine released by antigen-presenting cells in response to bacterial stimulation \[[@B11]\]. Also, genomewide association studies \[[@B12]\] have detected additional critical factors for the pathogenesis of UC. These include hepatocyte nuclear factor 4 (HNF4A), a protein regulating intercellular cell junctions, like desmosomes, tight and adherence junctions \[[@B13]\], and laminin *β*1 subunit (LAMB1), anchoring epithelium to the underlying basement membrane. Interestingly, laminin has been shown previously to be absent from the surrounding membranes in inflamed tissue section affected by UC \[[@B14]\]. Other genes identified in the association studies were E-cadherin (CDH1), a protein member of adherens junctions and transcription factor guanine nucleotide binding protein alpha 12 (GNA12). Common to HNF4A, LAMB1, CDH1, and GNA12 is the fact that these genes are all involved in the maintenance of intestinal epithelial cell integrity and barrier function \[[@B15]\].

The findings outlined above have defined the currently accepted hypothesis for the development of IBD, "Pathogenic intestinal bacteria and/or infectious agents initiate and perpetuate the inflammation of the gut through disruption of tolerance towards the commensal microbiota in an individual with genetic vulnerability." \[[@B16]\].

2. Dysbiosis in Ulcerative Colitis {#sec2}
==================================

Currently, it is not clear which factors initiate or maintain the inflammatory process in UC. There are opposing views whether an imbalance in gut flora even occurs in UC \[[@B17]\], but the evidence presented here does suggest that this is the case. Large epidemiological studies have addressed the question whether a trigger event lead to dysbiosis in UC. In a study from Spain with an average follow-up time of 3.5 years, the estimated incidence of developing both CD and UC was significantly elevated in patients with an identifiable episode of acute gastroenteritis \[[@B18]\]. For the control cohort without an episode of gastroenteritis, the incidence of IBD was calculated at 29.7/100,000 person years, but it increased to 68.4/100,000 person years for patients with previously identified episode of bacterial intestinal infection. In this study, the most commonly identified bacterial pathogen as a cause of enteric infection was *Campylobacter spp.*, followed by *Salmonella spp.* and *Shigella spp.*. Similarly, a gender and age-matched study from Denmark identified an increased risk for the development of CD and UC after infection with *Campylobacter spp.* or *Salmonella spp.*\[[@B19], [@B20]\]. The risk for CD and UC was highest during the first year following infection, in particular for inpatients, and remained elevated during the ensuing 15 years. These findings were disputed in another study from Denmark, which determined the incidence rate ratio of populations with or without exposure to *Campylobacter spp.* or *Salmonella spp.*\[[@B21]\]. Contrary to previously published results, the risk of developing CD and UC was found to be independent of positive or negative stool studies. The authors concluded that the increased discovery of previous *Campylobacter spp.* and *Salmonella spp.* infection at the time of diagnosis of CD or UC was due to increased rates of stool testing, consistent with detection bias.

However, it is still attractive to speculate that an acute enteric infection leads to possibly chronic changes in intestinal milieu and/or enteric microflora, or both. Indeed, there are a number of excellent studies that have investigated the quantitative and qualitative changes in the composition of the enteric flora in UC. Attempting to enumerate the number of bacteria in IBD patients, tissue samples were subjected to either enumeration by culture or quantitative rRNA hybridization \[[@B22]\]. Samples from both CD and UC subjects contained significantly more bacteria when compared to normal control tissue, and a gradual increase was observed from noninflamed to inflamed biopsy material \[[@B23]\]. In these experiments, imaging identified bacteria localized within the mucus layer without directly adhering to the underlying lamina propria. Additional results from another laboratory also showed increased bacterial adherence and invasion of epithelial cells and an enhanced inflammatory response \[[@B24]\]. Similarly, when determined by real-time quantitative PCR, biopsy samples from individuals with newly diagnosed UC harbored a significantly higher number of mucosa-associated bacteria in comparison to samples obtained from CD or healthy controls \[[@B25]\]. Similarly, 16S rRNA-based amplification revealed increased total CFU for aerobes, facultative anaerobes, and Gram negative bacteria in a pediatric population \[[@B26]\]. At the same time, a decreased number of *Bacteroides vulgatus* were amplified in comparison to healthy control subjects. In this study, the only Gram negative bacterial species identified in pediatric UC was *Escherichia coli*. In an opposing view, qualitative analysis revealed a similar distribution of unclassified *Bacteroidetes* in UC and healthy control samples \[[@B27]\]. Distinguishing between the microbiota of inflamed and noninflamed samples, it appears that with the onset of inflammation, bacterial diversity declines. These findings have been supported by other qualitative studies investigating the enteric flora of patients with UC. Denaturing gradient gel electrophoresis with universal and *Bacteroidetes*-specific primers and multivariant analysis revealed reduced diversity of predominant bacteria commonly found in healthy volunteers \[[@B28]\]. Species conspicuously absent from the enteric flora in 13 patients with documented UC included *Bacteroides vulgatus*, *B. ovatus*, *B. uniformis*, and *Parabacteroides spp.*. Similarly, in a landmark study by Frank et al., abnormal gut flora was identified in patients with CD and UC \[[@B29]\]. When subjected to culture-independent rRNA sequence analysis, common to both diseases was a reduction of phyla *Bacteroidetes* and *Firmicutes*. Both phyla promote gut health through the production of short-chain fatty acids, which are the primary energy source for intestinal epithelial cells, critical for the maintenance of barrier integrity \[[@B30], [@B31]\] and suppression of immune activation \[[@B32]\]. Depletion of short-chain fatty acid-producing organisms possibly deprives already vulnerable intestinal epithelial cells, leading to invasion of commensal or low-pathogenic bacteria with subsequent activation of immunocompetent cells.

But dysbiosis, as seen in UC, includes additional pathophysiological changes relevant to intestinal inflammation. Fluorescence in situ hybridization detected invasive bacteria in 83% of tissue samples from patients with UC as opposed to none in negative controls \[[@B33]\]. The organisms invading terminal ileum and colon of UC affected individuals were identified as *Proteobacteria*, *Clostridium*, *Enterobacteriae*, *Bacteroides*, and *Prevotella*. These investigations have opened additional trials attempting to identify a single or multiple disease-specific bacterial strains. A recently published study of twins affected and not affected by IBD-identified potentially pathogenic bacteria that were more frequently identified in patients suffering from UC \[[@B34]\]. These strains included *Rhodococcus spp.*, *Shigella spp.*, *Escherichia spp.*, and *Stenotrophomonas spp.*. At the same time, bacteria with anti-inflammatory properties were more frequently identified in siblings not affected by UC, including *Faecalibacterium prausnitzii*. A reduction in *F. prausnitzii* was recently shown to be associated with a higher risk of postoperative recurrence of CD, as documented by endoscopy at six months \[[@B35]\]. The proposed anti-inflammatory effect of *F. prausnitzii* was attributed to the attenuated activation of NF-**κ**B and MAP3K8, with subsequent reduction of IL-8 expression.

3. Specific Bacteria Increased in UC {#sec3}
====================================

Comparing gut tissue samples obtained from patients with both infectious diarrhea and UC microscopically, both diseases show a significant overlap in pathological findings \[[@B36]\]. PCR and sequencing analyses identified *Campylobacter spp.* in 74% of biopsy samples in a cohort of 69 patients with confirmed UC as opposed to 23% from healthy controls, even without the history of acute gastroenteritis \[[@B37]\]. Specifically, nested PCR for *Campylobacter concisus* was positive, and it was more common in UC samples when compared to healthy controls; 33% versus 11%, respectively. In addition, *Campylobacter ureolyticus* was positive in 22% of UC biopsy material compared to 3% of control samples, with supporting evidence in a similar study from India \[[@B38]\]. These findings led the authors to speculate that a specific immunological defect in UC results in the inability to eliminate *Campylobacter spp.*. Independent of the underlying host defect, a possible mechanistic explanation for a role of *Campylobacter spp.* in the pathogenesis of UC has recently been provided. *Campylobacter jejuni* was found to facilitate internalization and translocation of commensal, noninvasive *E. coli* strains via the transcellular and paracellular pathways in vitro and in vivo \[[@B39], [@B40]\]. These findings might indicate that in UC, *Campylobacter spp.* induce an inflammatory cascade that starts with an episode of acute gastroenteritis.

Besides *Campylobacter spp.*, ribosomal intergenic spacer analysis with subsequent sequencing analysis of unique PCR bands detected 3 to 4 logs higher abundance of *Enterobacteriae* belonging to the B2 and D phylogenetic groups in both CD and UC \[[@B41]\]. This might be in support of an argument for the role of specific bacteria in UC, as pathogenic *E. coli* strains belong predominantly to group B2 and to a lesser degree to group D. In a related study, *E. coli* isolates from patients with CD and UC displayed higher-adhesion indices in comparison to strains from normal controls \[[@B42]\]. *E. coli* associated with UC tissue harbor more adhesion/virulence determinants than strains from CD biopsy samples. More specifically, *E. coli* strains positive for pathogenicity factors *ompA*, *afae*, and *USP* were more likely to be identified in patients suffering from UC \[[@B43]\]. As mentioned before, these *E. coli* belonged to phylotype B2 and D, and were associated with active inflammation. This particular study also described an increased intracellular survival of invading *E. coli* in macrophage cultures in vitro, consistent with increased pathogenicity of UC bacterial isolates.

Adding to the list of potentially pathogenic bacteria in UC, PCR-based methods detected increased enterohepatic *Helicobacter* in subjects with CD and UC in comparison to members of the control population \[[@B44], [@B45]\]. In contrast to subjects suffering from IBD, the control population had a higher likelihood of infection with *Helicobacter pylori*. Given these results, the authors speculated that cytolethal toxin from enterohepatic *Helicobacter*plays a potential role in the intestinal inflammation of IBD. However, the molecular detection methods identifying *Campylobacter spp.*, *E. coli*, and enterohepatic *Helicobacter* in patients with UC await confirmation by an alternative method.

Alternatively, serological markers have been used to implicate specific bacterial strains in the pathogenesis of UC. *Bacteroides ovatus* caused an increased IgG and IgA antibody response in patients with IBD as opposed to normal controls \[[@B46]\]. This study identified and implicated a novel 19.5 kDa prominent antigen in the pathogenesis of both CD and UC. Similarly, UC patients were more likely to be seropositive for antibodies directed against *Fusobacterium varium* antigens (40%) in comparison to normal controls (16%) \[[@B47]\]. Correlating disease activity with seropositivity, patients with elevated *F. varium* immunoglobulins were more likely to be symptomatic and harbor extensive disease. In vitro investigations of *F. varium* by the same group have shown that this particular commensal strain invades epithelial cell lines, and induces expression of proinflammatory cytokine mRNAs, including IL-8, TNF-*α*, MCP-1, and IL-6 \[[@B48]\]. Further, in vivo experiments identified *F. varium* to produce very high concentrations of butyric acid, causing intestinal lesions in mice, similar to those observed in human UC \[[@B49]\]. In turn, elevated butyric acid was shown to increase the activity of proapoptotic pathways with subsequent erosions, a possible pathophysiological mechanism in UC \[[@B50]\]. These findings have led to three clinical trials investigating the efficacy of antibiotics in UC to specifically suppress *F. varium*\[[@B51]--[@B53]\]. Consistently, antimicrobial therapy resulted in significantly decreased CFUs and antibody titers directed against *F. varium*, improved endoscopic and histological scores, and clinical response at 12 months after treatment. In addition, patients treated with a combination of amoxicillin, tetracycline, and metronidazole for 14 days were more likely to discontinue steroid therapy at 3, 6, and 12 months.

4. Specific Bacteria Decreased in UC {#sec4}
====================================

It is becoming increasingly clear that the quality and quantity of intestinal microflora vary with disease activity, and active inflammation is not solely due to an increase of specific bacterial strains. During active UC, anti-inflammatory *Lactobacillus salivarius*, *L. manihotivorans*, and *Pediococcus acidilactici* were absent in fecal samples analyzed by fluorescence in situ hybridization \[[@B54]\]. With UC in remission, these strains reappeared. In a related study, *Bifidobacterium spp.* were identified in decreased numbers in both inflamed UC and CD while *Lactobacillus spp.* was unchanged during active UC \[[@B55]\]. The same study commented on the reduced thickness of the mucus layer when compared to controls.

5. Summary and Conclusion {#sec5}
=========================

Here we have discussed the roles of enteric bacteria in UC. The bacterial strains that have been associated with various roles are summarized in [Table 1](#tab1){ref-type="table"}. It is conceivable that pathogenic bacteria, including *Campylobacter spp.*, *Salmonella spp.,* and other currently unidentified pathogens, take the lead in initiating the inflammatory process in UC with an episode of acute gastroenteritis. Pathogenic and commensal strains and their effector proteins weaken the intestinal lining through production of high concentrations of butyric acid and translocation of nonpathogenic bacteria in genetically susceptible patients with a defect in the intestinal epithelial barrier function. Extensive immune activation due to breakdown of the intestinal barrier provides bacteria access to the gut mucosal immune system, resulting in uncontrolled inflammation and dysbiosis.
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###### 

Summary of enteric bacteria and their contribution to intestinal inflammation in UC.

  Role in UC                       Strain                 Location                             Reference
  -------------------------------- ---------------------- ------------------------------------ ----------------------------
  Initiation of inflammation       *Campylobacter spp.*   Europe                               \[[@B19], [@B20]\]
  *Salmonella spp.*                Europe                 \[[@B19], [@B20]\]                   
  *Shigella spp.*                  Europe                 \[[@B19], [@B20], [@B34]\]           
                                                                                               
  Proinflammatory                  *Campylobacter spp.*   Europe                               \[[@B37]\]
  *Escherichia coli*               Europe and America     \[[@B26], [@B34], [@B39]--[@B43]\]   
  *Rhodococcus spp.*               Europe                 \[[@B34]\]                           
  *Stenotrophomonas spp.*          Europe                 \[[@B34]\]                           
  Enterohepatic *Helicobacter*     Europe and America     \[[@B44], [@B45]\]                   
  *Bacteroides ovatus*             Asia                   \[[@B46]\]                           
  *Fusobacterium varium*           Asia                   \[[@B47]\]                           
                                                                                               
  Anti-inflammatory                *Bacteroides spp.*     Europe and America                   \[[@B26], [@B28], [@B29]\]
  *Firmicutes*                     America                \[[@B29]\]                           
  *Faecalibacterium prausnitzii*   Europe                 \[[@B34]\]                           
  *Lactobacillus spp.*             Europe                 \[[@B54]\]                           
  *Pediococcus acidilactici*       Europe                 \[[@B54]\]                           
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